SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Zim Laboratories - Quaterly Results

07 Aug 2026 Evaluate
The sales moved up 30.27% to Rs. 930.48 millions for the June 2026 quarter as compared to Rs. 714.28 millions during the year-ago period.The Net Loss for the quarter ended June 2026 is Rs. -38.74 millions as compared to Net Loss of Rs. -16.93 millions of corresponding quarter ended June 2025Operating Profit reported a sharp decline to 33.93 millions from 58.10 millions in the corresponding previous quarter.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202606 202506 % Var 202606 202506 % Var 202603 202503 % Var
Sales 930.48 714.28 30.27 930.48 714.28 30.27 3704.82 3756.36 -1.37
Other Income 9.86 14.76 -33.20 9.86 14.76 -33.20 113.90 56.21 102.63
PBIDT 33.93 58.10 -41.60 33.93 58.10 -41.60 409.70 488.90 -16.20
Interest 36.43 33.04 10.26 36.43 33.04 10.26 132.02 113.86 15.95
PBDT -2.50 25.06 -109.98 -2.50 25.06 -109.98 277.68 375.04 -25.96
Depreciation 51.71 47.90 7.95 51.71 47.90 7.95 193.67 198.91 -2.63
PBT -54.21 -22.84 137.35 -54.21 -22.84 137.35 84.01 176.13 -52.30
TAX -15.47 -5.91 161.76 -15.47 -5.91 161.76 24.35 58.68 -58.50
Deferred Tax -15.47 -5.91 161.76 -15.47 -5.91 161.76 -8.40 14.21 -159.11
PAT -38.74 -16.93 128.82 -38.74 -16.93 128.82 59.66 117.45 -49.20
Equity 535.49 487.26 9.90 535.49 487.26 9.90 535.00 487.26 9.80
PBIDTM(%) 3.65 8.13 -55.17 3.65 8.13 -55.17 11.06 13.02 -15.03

Zim Laboratories Share Price

110.65 -4.10 (-3.57%)
07-Aug-2026 10:19 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1944.85
Dr. Reddys Labs. 1163.40
Cipla 1465.60
Lupin 2400.90
Zydus Lifesciences 1102.35
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: